CUE
NASDAQCue Biopharma
$24.53
-2.56 (-9.45%)
2026-06-12 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$91.6M
P/E Ratio
N/A
52W Low
52W High
$0.17
$41.42
Volume
87K
Analyst Rating
Hold
Target: $41
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $4
Avg: $41
High: $115
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company ...
Employees
29
Website
cuebiopharma.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $27.5M | -96.6% | -$26.6M | -$21.5M |
| 2024 | $9.3M | -446.9% | -$40.7M | -$36.3M |
| 2023 | $5.5M | -949.9% | -$50.7M | -$40.0M |
| 2022 | $1.2M | -4275.1% | -$53.0M | -$41.6M |
| 2021 | $14.9M | -292.6% | -$44.2M | -$37.9M |
| 2026 Q1 | $5.7M | -94.3% | -$5.2M | -$10.8M |
| 2025 Q4 | $21.9M | 8.9% | $1.6M | -$1.1M |
| 2025 Q3 | $2.1M | -351.0% | -$7.4M | -$9.0M |
| 2025 Q2 | $3.0M | -292.3% | -$8.5M | -$3.4M |
| 2025 Q1 | $421K | -2921.4% | -$12.3M | -$8.0M |
| 2024 Q4 | $1.6M | -611.2% | -$9.5M | -$9.0M |
| 2024 Q3 | $3.3M | -264.2% | -$8.7M | -$7.5M |
| 2024 Q2 | $2.7M | -390.6% | -$10.2M | -$10.0M |